Newsfeeds Archive - Page 34 of 34

2 minute read

IDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors

July 27, 6:05 AM

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into a clinical trial collaboration and supply agreement with Amgen Inc.

AMGN

1 minute read

HC Wainwright Is Bullish On DICE Therapeutics – Read Why

By Vandana Singh

July 18, 3:31 PM

H.C. Wainwright analyst Emily Bodnar initiated coverage on DICE Therapeutics Inc (NASDAQ:DICE) with a Buy rating and a price target of $40 (150%…

AMGN

1 minute read

Morgan Stanley Maintains Equal-Weight on Amgen, Raises Price Target to $253

By Benzinga Newsdesk

July 15, 9:23 AM

Morgan Stanley analyst Matthew Harrison maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $239 to $253.

AMGN

1 minute read

Amgen Touts Early Lumakras Combo Data In KRAS Cancer Settings

By Vandana Singh

July 13, 1:41 PM

BMO Capital Markets says that while Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) + PD1i data was delayed to the August 7 presentation, it did get data on the Lumakras + SHP2 inhibitor combination.

AMGN

2 minute read

Amgen Whale Trades For July 12

By Benzinga Insights

July 12, 5:19 PM

Someone with a lot of money to spend has taken a bearish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

AMGN